CAR T-Cell Therapy Overview:
Chimeric antigen receptors (CARs) are recombinant receptors for antigens which redirect the specificity and function of T lymphocytes and/or other immune cells in a single molecule. CAR T-Cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signalling domains.
&nbsp;
CAR T-Cell Therapy Therapies: 450+
&nbsp;
CAR T-Cell Therapy Companies: 193+&nbsp;
&nbsp;
Key CAR T-Cell Therapy Companies
<ul>
<li>Alnylam Pharmaceuticals</li>
<li>JW Therapeutics</li>
<li>Gilead Sciences</li>
<li>Janssen Pharmaceuticals</li>
<li>Innovent Biologics</li>
<li>Sorrento Therapeutics</li>
<li>Cartesian Therapeutics</li>
<li>CASI Pharmaceuticals/Juventas Cell Therapy</li>
<li>Novartis</li>
<li>Poseida Therapeutics</li>
<li>Shanghai Unicar-Therapy Bio-medicine Technology</li>
<li>Sinobioway Cell Therapy Co., Ltd.</li>
<li>Tessa Therapeutics</li>
<li>Wuhan Bio-Raid Biotechnology</li>
<li>Miltenyi Biomedicine</li>
<li>Bristol-Myers Squibb</li>
<li>Autolus Limited</li>
<li>Beijing Immunochina Medical Science and Technology</li>
<li>Carsgen Therapeutics</li>
<li>Cellular Biomedicine Group</li>
<li>Chongqing Precision Biotech</li>
<li>Eureka Therapeutics</li>
<li>Formula Pharmaceuticals</li>
<li>Guangzhou Bio-gene Technology</li>
<li>Hebei Senlang Biotechnology</li>
<li>Mustang Bio</li>
<li>MolMed</li>
<li>Aurora BioPharma</li>
<li>Atara Biotherapeutics</li>
<li>Autolus</li>
<li>Bellicum Pharmaceuticals</li>
<li>Kecellitics Biotech Company Ltd</li>
<li>Yake Biotechnology</li>
<li>Minerva Biotechnologies</li>
<li>Allogene Therapeutics</li>
<li>PersonGen BioTherapeutics (Suzhou)</li>
<li>Precision BioSciences</li>
<li>Pregene (ShenZhen) Biotechnology Company</li>
<li>Shanghai GeneChem</li>
<li>Shanghai Longyao Biotechnology</li>
<li>Shenzhen BinDeBio</li>
<li>And several others.</li>
</ul>
&nbsp;
CAR T-Cell Therapy Report Assessment
<ul>
<li>Company Analysis</li>
<li>Therapeutic Assessment</li>
<li>Approved/Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
&nbsp;
CAR T-Cell Therapy Therapeutic Assessment:
<ul>
<li>By Product Type</li>
<li>By Stage and Product Type</li>
<li>By Route of Administration</li>
<li>By Stage and Route of Administration</li>
<li>By Molecule Type</li>
<li>By Stage and Molecule Type</li>
</ul>
&nbsp;
Related Reports:
<ul>
<li>Chimeric Antigen Receptor (CAR) T-Cell Therapy - Market Insight, Epidemiology and Market Forecast &ndash; 2032</li>
<li>CAR T-Cell Therapy for Acute Lymphoblastic Leukaemia (ALL) - Market Insight, Epidemiology And Market Forecast - 2032</li>
<li>CAR T-Cell Therapy for Multiple Myeloma - Market Insight, Epidemiology And Market Forecast - 2032</li>
<li>CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Market Insight, Epidemiology And Market Forecast - 2032</li>
<li>CAR-T - Pipeline Insight, 2022</li>
</ul>

CAR T-Cell Therapy Infographic

CAR T-Cell Therapy Pipeline

CAR T-Cell Therapy Infographic gives a brief about the treatment therapies, companies, overview and CAR T-Cell Therapy report features.